IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws: Change in Fiscal Year.

Story continues below

On December 13, 2018, the board of directors of Imprimis Pharmaceuticals, Inc. (the “Company”) took action to start the process by which the Company will change its name from “Imprimis Pharmaceuticals, Inc.” to “Harrow Health, Inc.” The Delaware General Corporations Law permits the Company to change its name by board action without the approval of the stockholders of the Company. It is anticipated that the name change will be completed within the next thirty days.

The stockholders of the Company need not take any action in respect of the name change. Additionally, once the name change is completed, stockholders do not need to exchange their certificates representing their shares of common stock. The current stock certificate will continue to represent their ownership interest in the Company. Stockholders, however, may return their certificates to the transfer agent for the Company after the name change is completed, and obtain an updated certificate with a new CUSIP number.

Item 7.01. Regulation FD Disclosure

Attached as Exhibit 99.1 to this Item 7.01 is a presentation of the Company, that is being used by the management of the Company at investor conferences and at meetings describing the Company.

The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

Imprimis Pharmaceuticals, Inc. Exhibit

To view the full exhibit click here


Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

An ad to help with our costs